Ventyx surges after Bristol rival's approval without black box warning

 Ventyx Biosciences Inc. shares rose 59% to $36.80 after analysts mentioned favorable signs related to the approval of Bristol Myers Squibb Co.'s psoriasis drug Sotyktu.

Stifel, Evercore ISI and Oppenheimer analysts noted that the U.S. Food and Drug Administration approval of the TYK2 inhibitor didn't include a black-box warning.

Jeff Jones and Leland Gershell at Oppenheimer wrote that "we see this as a significant win for deucravacinitib, VTYX and other TYK2 developers, substantially differentiating the TYK2 inhibitors from the JAK 1-3 inhibitors."

https://www.marketscreener.com/quote/stock/VENTYX-BIOSCIENCES-INC-128506325/news/Ventyx-Shares-Surge-59-After-Bristol-Myers-Drug-Approved-Without-Black-Box-Warning-41754939/